Wolverine Asset Management LLC Raises Stock Position in Emergent Biosolutions Inc. $EBS

Wolverine Asset Management LLC lifted its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 28.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 174,933 shares of the biopharmaceutical company’s stock after acquiring an additional 38,600 shares during the quarter. Wolverine Asset Management LLC owned approximately 0.32% of Emergent Biosolutions worth $1,116,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of EBS. Acadian Asset Management LLC increased its holdings in Emergent Biosolutions by 313.5% during the first quarter. Acadian Asset Management LLC now owns 833,316 shares of the biopharmaceutical company’s stock valued at $4,048,000 after buying an additional 631,794 shares during the period. Prescott Group Capital Management L.L.C. increased its holdings in Emergent Biosolutions by 198.9% during the first quarter. Prescott Group Capital Management L.L.C. now owns 627,671 shares of the biopharmaceutical company’s stock valued at $3,050,000 after buying an additional 417,671 shares during the period. Goldman Sachs Group Inc. increased its holdings in Emergent Biosolutions by 12.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock valued at $5,301,000 after buying an additional 121,583 shares during the period. New York State Common Retirement Fund increased its holdings in Emergent Biosolutions by 22.4% during the first quarter. New York State Common Retirement Fund now owns 375,034 shares of the biopharmaceutical company’s stock valued at $1,823,000 after buying an additional 68,748 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new position in Emergent Biosolutions during the second quarter valued at approximately $227,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a report on Wednesday, September 3rd. Weiss Ratings reissued a “sell (d)” rating on shares of Emergent Biosolutions in a report on Wednesday, October 8th. Finally, Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a report on Friday, October 24th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Emergent Biosolutions currently has a consensus rating of “Hold” and a consensus price target of $13.50.

Emergent Biosolutions Stock Down 3.2%

Emergent Biosolutions stock opened at $12.43 on Friday. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00. The stock has a market capitalization of $663.35 million, a price-to-earnings ratio of 9.56 and a beta of 2.04. Emergent Biosolutions Inc. has a 1-year low of $4.02 and a 1-year high of $13.41. The business has a fifty day moving average price of $8.93 and a 200-day moving average price of $7.40.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter. The business had revenue of $222.50 million during the quarter. Emergent Biosolutions had a return on equity of 21.43% and a net margin of 9.62%. Emergent Biosolutions has set its FY 2023 guidance at EPS. Equities research analysts forecast that Emergent Biosolutions Inc. will post -0.63 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Kathryn C. Zoon sold 7,086 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $8.87, for a total value of $62,852.82. Following the completion of the transaction, the director owned 71,799 shares in the company, valued at $636,857.13. This trade represents a 8.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Donald W. Degolyer sold 7,844 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $8.65, for a total value of $67,850.60. Following the completion of the transaction, the director owned 137,659 shares of the company’s stock, valued at $1,190,750.35. This trade represents a 5.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 45,538 shares of company stock worth $436,783 in the last 90 days. Insiders own 1.20% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.